These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 31335691

  • 41. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
    van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM, REPOSIT study group.
    BMC Cancer; 2017 Sep 15; 17(1):649. PubMed ID: 28915798
    [Abstract] [Full Text] [Related]

  • 42. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
    Kiamanesh Z, Ayati N, Sadeghi R, Hawkes E, Lee ST, Scott AM.
    Eur J Nucl Med Mol Imaging; 2022 Nov 15; 49(13):4661-4676. PubMed ID: 35932329
    [Abstract] [Full Text] [Related]

  • 43. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
    Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, Guminski AD, Long GV, Menzies AM.
    Ann Oncol; 2018 Oct 01; 29(10):2115-2120. PubMed ID: 30137228
    [Abstract] [Full Text] [Related]

  • 44. The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
    Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L.
    Clin Lung Cancer; 2021 Sep 01; 22(5):432-440. PubMed ID: 33879398
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L, Capozza A, Bandini M, Raggi D, Farè E, Pederzoli F, Gallina A, Capitanio U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, Giannatempo P, Serafini G, Padovano B, Salonia A, Briganti A, Montorsi F, Alessi A, Necchi A.
    Eur Urol Focus; 2021 Sep 01; 7(5):1092-1099. PubMed ID: 33172772
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. 18 F-FDG positron emission tomography-computed tomography has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stages IIB, IIC, and IIIA melanoma.
    Jaeger ZJ, Williams GA, Chen L, Mhlanga JC, Cornelius LA, Fields RC.
    J Surg Oncol; 2022 Mar 01; 125(3):525-534. PubMed ID: 34741547
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
    Seban RD, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, Schwartz LH, Gómez RGH, Saenger Y, Robert C, Ammari S, Dercle L.
    Eur J Nucl Med Mol Imaging; 2020 Sep 01; 47(10):2301-2312. PubMed ID: 32206839
    [Abstract] [Full Text] [Related]

  • 57. FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab.
    Iravani A, Wallace R, Lo SN, Galligan A, Weppler AM, Hicks RJ, Sandhu S.
    Radiology; 2023 May 01; 307(3):e221180. PubMed ID: 36853183
    [No Abstract] [Full Text] [Related]

  • 58. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kieker F, Dippel E, Rösch A, Simon JC, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D, Dermatologic Cooperative Oncology Group.
    Lancet; 2020 May 16; 395(10236):1558-1568. PubMed ID: 32416781
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.